Mollie N. Carruthers

TL;DR: This statement proposes a terminology scheme for the diagnosis of IgG4-related disease that is based primarily on the morphological appearance on biopsy, and advocates the use of strict criteria for accepting newly proposed entities or sites as components of the IgG 4- related disease spectrum.

TL;DR: John H. Stone, Arezou Khosroshahi, Vikram Deshpande, John K.Stone, Masayuki Takahira, Hisanori Umehara, George Webster, Motohisa Yamamoto, Eunhee Yi, Tadashi Yoshino, Giuseppe Zamboni, Yoh Zen, and Suresh Chari.

TL;DR: Rituximab appears to be an effective treatment for IgG4-RD, even without concomitant GC therapy.

TL;DR: Treatment with RTX led to prompt clinical and serologic improvement in refractory IgG4-RD in all patients with active inflammation, and Serial treatments with RTX may lead to progressive declines in serum IgG 4 concentrations and better disease control.

TL;DR: Multiple non-IgG4-RD conditions are associated with elevated serum IgG4, leading to poor specificity and low positive predictive value for this test, while a substantial subset of patients with biopsy-proven IgG 4-RD do not have elevated serum igG4.